This article was downloaded by: [Universite Laval] On: 16 July 2014, At: 03:14 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Nucleosides, Nucleotides and Nucleic Acids Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn20
Efficacy and Safety of a Urate Lowering Regimen in Primary Gout a
a
a
Rebeca Bailén , Nicolás M. González Senac , Mónica M. López , a
a
a
M. Luisa Llena , Marta Migoya , M. Teresa Rodríguez , Eugenio de b
c
Miguel , Rosa J. Torres & Juan G. Puig
a
a
Division of Internal Medicine, Metabolic-Vascular Unit, La Paz University Hospital, Madrid, Spain b
Division of Rheumatology, Madrid, Spain
c
Biochemistry, La Paz University Hospital, Madrid, Spain Published online: 18 Jun 2014.
To cite this article: Rebeca Bailén, Nicolás M. González Senac, Mónica M. López, M. Luisa Llena, Marta Migoya, M. Teresa Rodríguez, Eugenio de Miguel, Rosa J. Torres & Juan G. Puig (2014) Efficacy and Safety of a Urate Lowering Regimen in Primary Gout, Nucleosides, Nucleotides and Nucleic Acids, 33:4-6, 174-180, DOI: 10.1080/15257770.2013.853786 To link to this article: http://dx.doi.org/10.1080/15257770.2013.853786
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &
Downloaded by [Universite Laval] at 03:14 16 July 2014
Conditions of access and use can be found at http://www.tandfonline.com/page/termsand-conditions
Nucleosides, Nucleotides and Nucleic Acids, 33:174–180, 2014 C Taylor and Francis Group, LLC Copyright ISSN: 1525-7770 print / 1532-2335 online DOI: 10.1080/15257770.2013.853786
Downloaded by [Universite Laval] at 03:14 16 July 2014
EFFICACY AND SAFETY OF A URATE LOWERING REGIMEN IN PRIMARY GOUT
1 ´ 1 Nicolas ´ M. Gonzalez ´ ´ ´ Rebeca Bailen, Senac,1 Monica M. Lopez, 1 1 1 M. Luisa Llena, Marta Migoya, M. Teresa Rodr´ıguez, Eugenio de Miguel,2 Rosa J. Torres,3 and Juan G. Puig1 1 Division of Internal Medicine, Metabolic-Vascular Unit, La Paz University Hospital, Madrid, Spain 2 Division of Rheumatology and 3Biochemistry, La Paz University Hospital, Madrid, Spain
2
Background and Objectives. Pharmacologic urate lowering therapy (ULT), at full maintenance doses, has been associated with acute gout arthritis (in up to 80% of patients). The American College of Rheumatology has recently advocated gradually titrating the maintenance dose upward to chosen serum urate target. Few studies have examined the efficacy and safety of a ULT in primary gout. Patients and Methods. The ULT regimen examined included allopurinol (50 mg/day, with increases of 50 mg/month up to 300 mg/day) and colchicine, as prophylaxis to prevent acute gouty attacks. The efficacy and safety of this regimen was examined in 42 patients in whom allopurinol was withheld for ≥3 months and restarted after this assessment and followed up for 12 months. The efficacy and safety of the ULT regimen was related to the serum urate decrease and to the incidence of acute gout flares, respectively. Results. Fifty-nine patients (mean age 59 years, 56 men) with primary gout received the gradually titrated ULT regimen. Baseline serum urate was (mean ± SD) 8.4 ± 0.8 mg/dL. At 3, 6, 9, and 12 months serum urate fell by a mean of 1.8, 2.5, 2.7, and 2.5 mg/dL, respectively (p < 0.001). A serum urate level
Nucleosides, Nucleotides and Nucleic Acids Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn20
Efficacy and Safety of a Urate Lowering Regimen in Primary Gout a
a
a
Rebeca Bailén , Nicolás M. González Senac , Mónica M. López , a
a
a
M. Luisa Llena , Marta Migoya , M. Teresa Rodríguez , Eugenio de b
c
Miguel , Rosa J. Torres & Juan G. Puig
a
a
Division of Internal Medicine, Metabolic-Vascular Unit, La Paz University Hospital, Madrid, Spain b
Division of Rheumatology, Madrid, Spain
c
Biochemistry, La Paz University Hospital, Madrid, Spain Published online: 18 Jun 2014.
To cite this article: Rebeca Bailén, Nicolás M. González Senac, Mónica M. López, M. Luisa Llena, Marta Migoya, M. Teresa Rodríguez, Eugenio de Miguel, Rosa J. Torres & Juan G. Puig (2014) Efficacy and Safety of a Urate Lowering Regimen in Primary Gout, Nucleosides, Nucleotides and Nucleic Acids, 33:4-6, 174-180, DOI: 10.1080/15257770.2013.853786 To link to this article: http://dx.doi.org/10.1080/15257770.2013.853786
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &
Downloaded by [Universite Laval] at 03:14 16 July 2014
Conditions of access and use can be found at http://www.tandfonline.com/page/termsand-conditions
Nucleosides, Nucleotides and Nucleic Acids, 33:174–180, 2014 C Taylor and Francis Group, LLC Copyright ISSN: 1525-7770 print / 1532-2335 online DOI: 10.1080/15257770.2013.853786
Downloaded by [Universite Laval] at 03:14 16 July 2014
EFFICACY AND SAFETY OF A URATE LOWERING REGIMEN IN PRIMARY GOUT
1 ´ 1 Nicolas ´ M. Gonzalez ´ ´ ´ Rebeca Bailen, Senac,1 Monica M. Lopez, 1 1 1 M. Luisa Llena, Marta Migoya, M. Teresa Rodr´ıguez, Eugenio de Miguel,2 Rosa J. Torres,3 and Juan G. Puig1 1 Division of Internal Medicine, Metabolic-Vascular Unit, La Paz University Hospital, Madrid, Spain 2 Division of Rheumatology and 3Biochemistry, La Paz University Hospital, Madrid, Spain
2
Background and Objectives. Pharmacologic urate lowering therapy (ULT), at full maintenance doses, has been associated with acute gout arthritis (in up to 80% of patients). The American College of Rheumatology has recently advocated gradually titrating the maintenance dose upward to chosen serum urate target. Few studies have examined the efficacy and safety of a ULT in primary gout. Patients and Methods. The ULT regimen examined included allopurinol (50 mg/day, with increases of 50 mg/month up to 300 mg/day) and colchicine, as prophylaxis to prevent acute gouty attacks. The efficacy and safety of this regimen was examined in 42 patients in whom allopurinol was withheld for ≥3 months and restarted after this assessment and followed up for 12 months. The efficacy and safety of the ULT regimen was related to the serum urate decrease and to the incidence of acute gout flares, respectively. Results. Fifty-nine patients (mean age 59 years, 56 men) with primary gout received the gradually titrated ULT regimen. Baseline serum urate was (mean ± SD) 8.4 ± 0.8 mg/dL. At 3, 6, 9, and 12 months serum urate fell by a mean of 1.8, 2.5, 2.7, and 2.5 mg/dL, respectively (p < 0.001). A serum urate level
